Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Acotec Scientific Holdings Limited ( (HK:6669) ) has shared an announcement.
Acotec Scientific Holdings Limited has announced the approval of its Sirolimus-Coated Coronary Balloon Dilatation Catheter, AcoArt Canna®, by the PRC National Medical Products Administration. This device is designed for treating de novo coronary artery bifurcation lesions and has shown efficacy and safety in clinical trials. The company plans to initiate marketing activities in the Chinese market, although there is no guarantee of successful commercialization.
More about Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited is a company incorporated in the Cayman Islands, operating in the medical device industry. The company focuses on developing innovative medical products, including devices for coronary artery treatments, and is actively involved in the Chinese market.
YTD Price Performance: 103.02%
Average Trading Volume: 394,206
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.8B
Find detailed analytics on 6669 stock on TipRanks’ Stock Analysis page.